Fresenius SE KGaACHIX:FRED 72 EBITDA Margin % is 15.02% as of Mar. 2026, which is 19% below its 10-year median of 18.46. GuruFocus rates CHIX:FRED with a GF Score™ of 72/100 and a GF Value™ of €33.98 (Fairly Valued). The stock has 5 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Fresenius SE KGaA ranks better than 64.67% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Fresenius SE KGaA's EBITDA for the
three
months ended in Mar. 2026 was €874 Mil. Fresenius SE KGaA's Revenue for the
three
months ended in Mar. 2026 was €5,818 Mil. Therefore, Fresenius SE KGaA's EBITDA margin for the quarter that ended in Mar. 2026 was 15.02%.
Fresenius SE KGaA (CHIX:FREd) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Fresenius SE KGaA EBITDA Margin % Related Terms
Fresenius SE KGaA EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Fresenius SE KGaA's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:FRED vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Fresenius SE KGaA's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius SE KGaA EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius SE KGaA's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Fresenius SE KGaA's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresenius SE KGaA (CHIX:FRED) has a EBITDA Margin % of 15.02% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fresenius SE KGaA and its competitors. This is 19% below median its historical median of 18.46. Over the past decade, Fresenius SE KGaA's EBITDA Margin % has ranged from 12.78 to 21.18. According to the industry distribution chart, Fresenius SE KGaA ranks #236 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 35.3%.
Is Fresenius SE KGaA's EBITDA Margin % too high?
Fresenius SE KGaA's current EBITDA Margin % of 15.02% is 19% below median its 10-year median of 18.46. Over the past 10 years, this metric has ranged from a low of 12.78 to a high of 21.18. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Fresenius SE KGaA's value of 15.02% is 47.1% above this industry median. Based on the distribution chart, Fresenius SE KGaA ranks #236 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Fresenius SE KGaA has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius SE KGaA ranks #236 out of 668 companies for EBITDA Margin %. This puts Fresenius SE KGaA in the upper half of its industry. The industry median EBITDA Margin % is 10.21. Fresenius SE KGaA's value of 15.02% is 47.1% above this benchmark. Historically, Fresenius SE KGaA's own EBITDA Margin % has ranged from 12.78 to 21.18 over the past decade. While the company's 10-year median is 18.46 vs. the industry median of 10.21, Fresenius SE KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fresenius SE KGaA's current EBITDA Margin % of 15.02% is 47.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fresenius SE KGaA and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius SE KGaA's current EBITDA Margin % is 15.02%, which is 19% below median its own 10-year median of 18.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Based on GuruFocus' analysis, Fresenius SE KGaA (CHIX:FRED) is currently considered Fairly Valued. The stock's GF Value™ is €33.98, compared to a current price of €37.10 — trading 9.2% above its estimated fair value. The current EBITDA Margin % is 15.02%, which is 19% below median its 10-year median of 18.46 and 47.1% above the Healthcare Providers & Services industry median of 10.21. Fresenius SE KGaA's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Fresenius SE KGaA (CHIX:FRED), the current EBITDA Margin % is 15.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius SE KGaA (CHIX:FRED) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued.
The current stock price of €37.10 is trading 9.2% above its estimated GF Value™ of €33.98.
GuruFocus considers Fresenius SE KGaA to be Fairly Valued.
Key valuation signals for CHIX:FRED:
EBITDA Margin %: 15.02% (19% below median its 10-year median of 18.46)
GF Value™: €33.98 vs. price of €37.10 (9.2% above fair value)
Industry Position: 47.1% above the Healthcare Providers & Services median (#236 of 668)
No single metric tells the full story. See the CHIX:FRED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
72GF Score
Get the complete analysis for CHIX:FRED
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:FRED has been successfully added to your 
